Prenetics Global signs “transformational” $200mln deal to create cancer screening JV

–News Direct–

Prenetics Global Ltd (NASDAQ:PRE) CEO Danny Yeung speaks to Thomas Warner from Proactive after announcing a $200mln deal to create a multi-cancer early detection screening joint venture with Professor Dennis Lo. The new JV will be called Insighta and Yeung will serve as its first CEO. Yeung reveals plans to launch tests targeting lung and liver cancer in 2025, with a goal of selling over 30 million tests annually by 2030.

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

View source version on

Prenetics Global Ltd

comtex tracking


You may also like...